| Disease | IN THIS DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED CROSSOVER DESIGN 25 PATIENTS WITH MILD TO MODERATE UNTREATED PRIMARY HHYPERCHOLESEROLEMIA WERE STUDIED. THE ACTIVE GARLIC PREPARATION CONTAINED 5 MG STEAMED DISTILLED GARLIC OIL, CORRESPONDING
TO A DAILY DOSE OF 4000 UNITS OF ALLICIN-EQUIVALENTS. AFTER A SINGLE BLIND 4-WEEK RUN-IN PERIOD WITH PLACEBO, A 12-WEEK TREATMENT PERIOD WITH EITHER ACTIVE OR PLACEBO PREPARATION FOLLOWED. AFTER ANOTHER SINGLE-BLIND 4-WEEK WASHOUT PERIOD WITH
PLACEBO, A CROSSOVER 12-WEEK TREATMENT PERIOD FOLLOWED. LIPOPROTEINS WERE MEASURED AT THE BEGINNING AND END OF EVERY PHASE REPEATEDLY ON INDEPENDENT DSYS. CHOLESTEROL SYNTHESIS AND ABSORPTION WERE MEASURED USING FECAL BALANCE AND A DOUBLE-
ISOTOPE CONTINUOUS FEEDING METHOD EMPLOYING DEUTERATED CHOLESTEROL AND SITOSTANOL, RESPECTIVELY, AT THE END OF EVERY 12-WEEK TREATMENT PERIOD. AS AN ADDITIONAL CHOLESTEROL SYNTHESIS SHORT-TERM MARKER, THE 24-H URINARY EXCRETION OF MEVALONIC
ACID AND THE CHOLESTEROL PRECURSOR LATHOSTEROL WERE DETERMINED IN PLASMA. NONE OF THE PARAMETERS WERE INFLUENCED BY PLACEBO OR ACTIVE DRUG.
A COMMERCIAL PRODUCT, TEGRA, WAS USED. |